Sage Therapeutics, Inc. (SAGE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 12.95 |
| Open | 13.52 |
| Bid | 13.98 x 500 |
| Ask | 14.03 x 500 |
| Day's range | 13.45 - 14.52 |
| 52-week range | 10.92 - 59.99 |
| Volume | |
| Avg. volume | 1,028,553 |
| Market cap | 841.494M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.05 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.31 |
ZacksSage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
ZacksSage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investor's Business DailySage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Sage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study, and Sage stock collapsed to a record low.
© 2024 Yahoo. All rights reserved.